(Q34458111)

2 August 2017

1 reference

title

Recombinant factor VIIa (Novoseven) as a hemostatic agent (English)

1 reference

2 August 2017

U Hedner

1

1 reference

2 August 2017

publication date

1 October 2001

1 reference

2 August 2017

published in

Seminars in Hematology

1 reference

2 August 2017

volume

38

1 reference

2 August 2017

issue

4 Suppl 12

1 reference

2 August 2017

page(s)

43-47

1 reference

Effect of Dextran on Factor VIII (Antihemophilic Factor) and Platelet Function

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

NovoSeven in warfarin-treated patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

Clinical use of recombinant FVIIa (rFVIIa).

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

Use of recombinant factor VIIa in surgery in factor-VII-deficient patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

Treatment of traumatic bleeding with recombinant factor VIIa.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

Platelet activity of high-dose factor VIIa is independent of tissue factor

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

Successful use of recombinant FVIIa (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990147-7

7 January 2021

10.1016/S0037-1963(01)90147-7

Identifiers

DOI

1 reference

2 August 2017

1 reference